Navigation Links
Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
Date:3/14/2008

acne and burns.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com .

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release, include, without limitation, the timely completion of the study injections, the timely completion of the overall acne study, the timely completion of the Company's Phase III wrinkle study, and the Company's ability to raise additional funding, whether through strategic partners for outlicensing, by selling its Swiss facility, or otherwise. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward- looking statements rely on a number of assumpti
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
2. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
3. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
4. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
5. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
8. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
9. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
10. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 Apnea Sciences ( www.apneasciences.com ... in Aliso Viejo , California.  ... the tremendous growth and worldwide expansion, a new facility ... SnoreRx, the anti snore cure have exceeded our expectations ... "We are now in 23 countries and will be ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... Texas, Sept. 29 Luminex Corporation (Nasdaq: ... 2010 Prix Galien USA Award for its innovative xTAG® ... named Best Medical Technology at the Prix Galien USA ... 2010, at the American Museum of Natural History in ...
... asked today to make protecting the eyes from ... by increasing the prevalence of UV and eye-health ... as the Surgeon General, and in upcoming healthcare ... the Congressional Vision Caucus, provided the opening remarks ...
Cached Medicine Technology:Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award 2Prevent Blindness America Issues Call-to-Action to Make UV Eye Protection a National Health Priority 2Prevent Blindness America Issues Call-to-Action to Make UV Eye Protection a National Health Priority 3
(Date:12/24/2014)... Epigenetics finds applications in a large number of ... developmental biology, and research for metabolic and genetic disorders. ... widely used techniques for the discovery and development of ... is rapidly growing worldwide. In 2012, there were 14.1 ... 32.6 million people living with cancer (within five years ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Dr. Vu ... the expansion of his practice and med-spa with the ... practice’s growing list of cosmetic treatments and services. , ... into the skin,” says Dr. Ho. “As a result ... such as wrinkles, sun spots, discolorations or blemishes.” , ...
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
(Date:12/24/2014)... new, injectable weight-loss drug has been approved by the ... Tuesday approved Saxenda (liraglutide) for adults who are obese ... least one weight-related health condition, such as high blood ... taking the drug, made by Novo Nordisk, should still ... noted. "Obesity is a public health concern and ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay ... call for giving the cholesterol-lowering drugs known as statins to ... These new standards bring the association in line with the ... recommend giving low- or high-dose statins to all people at ... agree that the decision to start a statin should be ...
Breaking Medicine News(10 mins):Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3
... published in the September Journal of Nuclear Medicine ... role in the evaluation and treatment planning for a ... According to researchers, molecular imaging allows physicians to ... turn, provide patients with personalized care. In addition, molecular ...
... Faith based schools are on the rise in ... values at odds with legislation on equality? Research that ... Leadership published by SAGE shows what happens when school ... consequences for gay students and staff. The UK ...
... cause of cancer deaths worldwide, and the prognosis is ... incidence of one type of lung cancer, adenocarcinoma, has ... the changes in tumor cell biology that result in ... mass of tissue) that have been completely surgically removed ...
... Implementation of staggered radiologist work shifts can expedite the ... to a study in the September issue of the ... ( www.jacr.org ). Radiology practice in the ... it has maximized coverage for imaging such as computed ...
... HealthDay Reporter , TUESDAY, Aug. 31 (HealthDay News) ... strong policy statement directed toward pediatricians, parents and the media ... getting about sex from television, the Internet and other media ... , was published online Aug. 30 and in the September ...
... Health and University of Chicago have found a promising ... of skin and soft-tissue damage caused by USA300, the ... in the United States. By neutralizing a key toxin ... reduce the damaging effects of the infection on skin ...
Cached Medicine News:Health News:Personalized medicine: Molecular imaging predicts treatment success in many cancers 2Health News:Personalized medicine: Molecular imaging predicts treatment success in many cancers 3Health News:Keeping faith -- schools must balance ethos with equality 2Health News:Tumor budding identified as predictor for unfavorable outcome in lung cancer 2Health News:Staggered radiologist work shifts improve patient care, study suggests 2Health News:U.S. Pediatricians Decry Media's Portrayal of Sex 2Health News:U.S. Pediatricians Decry Media's Portrayal of Sex 3Health News:Treatment for S. aureus skin infection works in mouse model 2Health News:Treatment for S. aureus skin infection works in mouse model 3
Disposable Microscissors: Horizontal, Curved...
Disposable Microscissors: Horizontal, Straight...
Disposable Microscissors: Vertical, 90...
Low profile, sharp-tipped scissors with a vertical cutting action. Excellent for peeling and cutting fine epiretinal membranes....
Medicine Products: